Wednesday, November 9, 2016
Sorrento Therapeutics Acquires Scilex
San Diego-based Sorrento Therapeutics said on Tuesday that it has acquired a majority of Scilex Pharmaceuticals, a developer of a lidocaine patch being used to treat postherpetic neuralgia, the chronic pain that sometimes develops with shingles. The deal was worth approximately $47.6M, and was split between both cash and stock. The deal had originally been announced in August.
Support Our Coverage Of SoCal's Tech Ecosystem!
Tap into Southern California's growing tech ecosystem, by signing up for a two week free trial membership. Find new tech customers, find high tech startups and jobs, find venture funding, help support our news coverage!Learn More